SNIPR today announced the publication of a peer-reviewed expanded access case report in Clinical Infectious Diseases describing the use of SNIPR001 in a kidney transplant recipient with progressive, multidrug-resistant Escherichia coli malakoplakia, a rare disease characterized by intracellular bacterial persistence.
Expanded Access Case Report of SNIPR001, an Engineered CRISPR Medicine, in Rare Intracellular E. coli Disease Published in Clinical Infectious Diseases
Previous
Previous
SNIPR enrolls first patient in Phase 2 portion of SNIPR001 trial, expanding study to 66 patients
Next
Next